Araceli Biosciences Secures $4.5 Million Financing Round Supported by Jeff Swickard
Araceli Biosciences has closed a $4.5 million financing round, with investor Jeff Swickard joining the company's backing. The funding comes during a period of significant commercial expansion for the Oregon-based firm; Araceli projects its 2026 revenue to be six times higher than it was two years ago. The capital will support the company's transition into 'phase two' of commercialization, which involves launching consumable products for its existing customer base and preparing for a broader rollout in 2027. Araceli’s Endeavor platform utilizes AI-driven cellular imaging to enable New Approach Methodologies (NAMs), allowing pharmaceutical companies to test drug safety using human cell-based assays rather than traditional animal models. Currently, the company's technology is utilized by 10 of the world's top 20 pharmaceutical organizations. The investment aims to scale Araceli's ability to provide faster, more accurate biological data for drug discovery across North America and Europe.
Topics: biotechnology cellular imaging drug discovery funding round venture capital